Age>18, in-patients with candidemia or with invasive candida infections with positive blood or tissue culture, fever or hypothermia or hypotension, or local signs, not to participate in any other clinical trial.

Women pregnant or breastfeeding, allergy to azole or echinocandin, patients for whom caspofungin or voriconazole in contraindicated, high risk for QTc prolonguation, Hepatic dysfunction, concomitant use of inducers drugs in 5 days of drug, sole diagnosis of mucocutaneous or UTI candida, candidemia that failed previous antifungal therapy, invasive fungal disease other than candida, alternative etiology to the patient's symptoms, patients who received systemic antifungals, immunosupresion, fungal endocarditis, osteomyelitis, meningitis, low life expectency, risky concomitant medical condition, previously enrolled in a phase II study with isavuconazole, enroolled in another clinical trial, weight<40 kg, congenital QT syndrome.